Acesso livre
Acesso livre

Medicina de Emergências

Estudo randomizado | Molnupiravir reduziu o risco de internação ou morte por Covid-19 de pacientes adultos não vacinados sob risco (p.ex., com obesidade, idade acima de 60 anos etc.).

17 Dez, 2021 | 12:28h

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Conteúdo relacionado: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (vários artigos sobre o tema)

Diretriz NICE | Insuficiência cardíaca aguda: diagnóstico e tratamento.

17 Dez, 2021 | 12:16h

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Conteúdo relacionado: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

Retrospectiva: principais artigos de 2021 sobre doenças infecciosas além da COVID.

17 Dez, 2021 | 12:06h

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Comentário no Twitter

 

Medicamento da Merck contra COVID perde seu brilho: o que isso significa para a pandemia – “Molnupiravir foi inicialmente anunciado pelos oficiais de saúde pública como um elemento que mudaria o cenário da COVID-19, mas dados finais dos estudos clínicos mostraram eficácia abaixo das expectativas.”

16 Dez, 2021 | 13:04h

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Conteúdos relacionados:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Encefalite autoimune após infecção por SARS-CoV-2: frequência de casos, achados e desfechos.

16 Dez, 2021 | 13:01h

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Comentário no Twitter

 

[Comunicado de imprensa – ainda não publicado] Em análise final, pílula da Pfizer contra Covid mantém a eficácia de 89% em reduzir o risco de internação ou morte.

15 Dez, 2021 | 12:47h

Comunicado de imprensa: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Comentários:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Conteúdos relacionados:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

 

Comentário no Twitter (fio – clique para saber mais)

 

Posicionamento científico | Diagnóstico, tratamento e prevenção da ingestão de baterias na infância.

15 Dez, 2021 | 12:33h

Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood: A European Society for Paediatric Gastroenterology Hepatology and Nutrition Position Paper – Journal of Pediatric Gastroenterology and Nutrition

Resumo visual: Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood

 

Comentário no Twitter (fio – clique para saber mais)

 

Revisão | Diagnóstico e tratamento da apendicite aguda em adultos.

15 Dez, 2021 | 12:30h

Diagnosis and Management of Acute Appendicitis in Adults: A Review – JAMA (gratuito por tempo limitado)

Entrevista com o autor: Current Management of Acute Appendicitis: Antibiotics or Surgical Intervention

Comentário: Antibiotics can be first-line therapy for uncomplicated appendicitis cases – Duke University Medical Center

COVID-19 e trombose: busca por evidências.

13 Dez, 2021 | 11:35h

COVID-19 and thrombosis: searching for evidence – Hematology, ASH Education Program

Como reconhecer e tratar a coagulopatia associada a COVID-19.

13 Dez, 2021 | 11:34h

How to recognize and manage COVID-19-associated coagulopathy – Hematology, ASH Education Program

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.